15th international congress

15th International Congress Themed Courses Streaming Content

Pricing - MDS members: Free; Non-Members: $65 USD

The 15th International Congress Themed Courses streaming content includes the following sessions:

Cognitive decline in movement disorders

Chairs:
David Burn
Newcastle upon Tyne, United Kingdom
Dennis Dickson
Jacksonville, FL, USA

Anatomical substrate of cognitive decline in parkinsonian disorders
Kenji Kosaka
Yokohama, Japan

The clinical spectrum of dementia in parkinsonian disorders
Bruno Dubois
Paris, France

Current and future treatment of cognitive deficits in Lewy body dementias
Murat Emre
Capa Istanbul, Turkey

At the conclusion of this session, participants should be better able to:

  1. Describe the neuropathology of parkinsonian disorders in which cognitive dysfunction is an important clinical components
  2. Describe the clinical features, differential diagnosis and investigations of dementia in parkinsonian disorders
  3. Discuss the current and future treatment of Lewy body dementias
Gilles de la Tourette syndrome

Chairs:
Jonathan Mink
Rochester, NY, USA
Paul Sandor
Toronto, ON, Canada

The circuitry of behavioral disorders: From animal models to Tourette syndrome
Yulia Worbe
Paris, France

Clinical features of Tourette syndrome
Mary Robertson
London, United Kingdom

Update on treatments in Tourette syndrome
Jonathan Mink
Rochester, NY, USA

At the conclusion of this session, participants should be better able to:

  1. Describe the neural networks involving Tourette syndrome: Evidence from animal models to neuroimaging
  2. Describe the clinical features of Tourette syndrome, the role of genetics or environmental factors
  3. Describe the treatments for Tourette syndrome
Psychiatric features of genetic movement disorders

Chairs:
Valerie Voon
Cambridge, United Kingdom
Sylvain Chouinard
Montreal, QC, Canada

Huntington's disease
Michael Orth
Ulm, Germany

Genetic parkinsonisms
Meike Kasten
Lübeck, Germany

Genetic dystonias
Mateusz Zurowski
Toronto, ON, Canada

At the conclusion of this session, participants should be better able to:

  1. Recognize the importance of psychiatric features in three genetic movement disorders: Huntington's disease, genetic parkinsonisms, and genetic dystonias.
  2. Define the clinical spectrum of psychiatric features in these genetic movement disorders
  3. Discuss the diagnostic and management strategies of psychiatric features in these genetic movement disorders
Bedside evaluation of cognition in movement disorders

In this interactive session, we will make the transition from theory to clinical practice and demonstrate strategies to evaluate cognition in different movement disorders. The administration and interpretation of bedside tests will be reviewed and demonstrated. Participants are encouraged to interact with the faculty and to share their approaches for group discussion and commentary.

Thomas Bak
Edinburgh, United Kingdom
Karen Marder
New York, NY, USA

At the conclusion of this session, participants should be better able to:

  1. Recognize the range of cognitive deficits in patients with dementia and Parkinson's disease
  2. Elicit key cognitive deficits in Parkinson's disease patients through simple bedside tests
  3. Interpret neuropsychometric reports on patients with Parkinson's disease and related disorders
Impulsivity, addiction and reward mechanisms in movement disorders

Chairs:
Andrew Lees
London, United Kingdom
Marie Vidailhet
Paris, France

Neurochemistry and circuitry involved in reward mechanisms
T. Celeste Napier
Chicago, IL, USA

Genetic factors in ICD and addiction disorders
James Kennedy
Toronto, ON, Canada

Clinical manifestations of ICDs and dopamine dysregulation syndrome in Parkinson's disease
Andrew Siderowf
Philadelphia, PA, USA

At the conclusion of this session, participants should be better able to:

  1. Identify the networks involved in reward mechanisms
  2. Discuss the role of genetic factors in vulnerability to impulse control disorders (ICD) and addiction
  3. Describe the clinical features of impulse control disorders and addiction to dopaminergic agents
An update on psychogenic movement disorders

Chairs:
Kapil Sethi
Augusta, GA, USA
Joseph Jankovic
Houston, TX, USA

An update on clinical features and diagnostic criteria of psychogenic movement disorders
Anthony Lang
Toronto, ON, Canada

The pathophysiology of conversion disorders
Valerie Voon
Cambridge, United Kingdom

Modern management of psychogenic movement disorders
Jon Stone
Edinburgh, United Kingdom

At the conclusion of this session, participants should be better able to:

  1. Recognize the clinical spectrum of psychogenic movement disorders
  2. Discuss possible causes and pathophysiology
  3. Describe how to manage a patient with psychogenic movement disorder
Hallucinations and psychosis in Parkinson's disease

Chairs:
Gilles Fénelon
Créteil, France
Oscar Gershanik
Buenos Aires, Argentina

Epidemiology and phenomenology of psychosis in Parkinson's disease
Gilles Fénelon
Créteil, France

Is there something you aren't telling me? Detecting psychotic symptoms in Parkinson's disease
Nico Diederich
Luxembourg City, Luxembourg

Treatment of psychosis in Parkinson's disease: Current agents and future directions
Joseph Friedman
Warwick, RI, USA

At the conclusion of this session, participants should be better able to:

  1. Describe the frequency and nature of psychotic symptoms in Parkinson's disease
  2. Better able to identify psychotic symptoms
  3. Discuss current treatments for the management of psychosis and appreciate their shortcomings
Impulse control disorders (ICDs)

Chairs:
Janis Miyasaki
Toronto, ON, Canada
Daniel Weintraub
Philadelphia, PA, USA

The clinical spectrum of ICDs and dopamine dysregulation syndrome (DDS)
Mark Stacy
Durham, NC, USA

How to detect ICDs in Parkinson's disease
Daniel Weintraub
Philadelphia, PA, USA

How to manage ICDs in Parkinson's disease
Andrew Evans
Parkville, Australia

At the conclusion of this session, participants should be better able to:

  1. Discuss the relationship between ICDs and dopamine dysregulation syndrome (DDS) in Parkinson's disease
  2. Identify behaviors suggestive of ICD and DDS
  3. Describe the management of ICD and DDS
Psychogenic movement disorders: Video demonstrations and evaluation techniques

In this interactive session, the phenomenology and methods of examining subjects with psychogenic movement disorders will be presented using video case examples.

David Riley
South Euclid, OH, USA
Mark Edwards
London, United Kingdom

At the conclusion of this session, participants should be better able to:

  1. Identify the phenomenology of psychogenic movement disorders
  2. Recognize the differences between organic and non-organic movement disorders
  3. Know how to examine a patient with a suspected psychogenic movement disorders
The non-dementia associated cognitive and behavioral features of Parkinson's disease

Chairs:
Dag Aarsland
Stavanger, Norway
Roger Barker
Cambridge, United Kingdom

Dopamine and cognition: What have we learned from experimental studies?
Roshan Cools
Nijmegen, Netherlands

Mild Cognitive Impairment in Parkinson's disease: What does it mean?
Dag Aarsland
Stavanger, Norway

Cognitive and behavioral problems related to STN DBS in Parkinson's disease
Paul Krack
Grenoble, France

At the conclusion of this session, participants should be better able to:

  1. Describe the role of dopamine in normal cognitive processes
  2. Recognize the entity and significance of Mild Cognitive Impairment (MCI) of Parkinson's disease
  3. Identify the cognitive and behavioral problems related to surgery for Parkinson's disease
Startle, stereotypies and mannerisms: Video cases

In this interactive session, the phenomenology, clinical features and neurophysiology of abnormal startle, stereotypies and mannerisms will be reviewed using video examples.

Marie Saint-Hilaire
Boston, MA, USA
Kapil Sethi
Augusta, GA, USA

At the conclusion of this session, participants should be better able to:

  1. List the classification of neuropsychiatric hyper-startles and their cross cultural variations
  2. Discuss the neurophysiological mechanisms by which abnormalities of the startle response may occur
  3. Describe the recent advances in understanding the clinical features, prevalence, and outcomes of motor stereotypy disorders
Mood changes in Parkinson's disease: Depression, anxiety and apathy

Chairs:
Jaime Kulisevsky
Barcelona, Spain
Paolo Barone
Naples, Italy

Depression in Parkinson's disease
Paolo Barone
Naples, Italy

Anxiety in Parkinson's disease
Jaime Kulisevsky
Barcelona, Spain

Apathy in Parkinson's disease
Sergio Starkstein
Crawley, Australia

At the conclusion of this session, participants should be better able to:

  1. 1. Recognize that neuropsychiatric symptoms are common in Parkinson's disease, even at the earliest stages, and have important consequences for quality of life and daily functioning
  2. Compare the epidemiology, diagnostic criteria, and clinical course of depression, anxiety and apathy in Parkinson's disease
  3. Discuss the evidence for management of these neuropsychiatric symptoms in Parkinson's disease